TP53 and cancer: To ascertain the impact of p110α activating mutations in tumor initiation and progression, we combined myr-p110α with frequently co-occurring mutations of two genes, p53 and Kras, to generate novel models of breast, lung and potentially other cancers whose induction is controlled by the researcher.